Group 1 - Hanyu Pharmaceutical experienced a 5.02% increase in stock price, reaching 21.97 CNY per share, with a trading volume of 655 million CNY and a turnover rate of 4.05%, resulting in a total market capitalization of 19.405 billion CNY [1] - Hanyu Pharmaceutical, established on April 2, 2003, and listed on April 7, 2011, is located in Longhua District, Shenzhen, Guangdong Province, and primarily engages in chemical pharmaceuticals and medical devices, with 100% of its revenue derived from the pharmaceutical manufacturing sector [1] Group 2 - According to data from the top ten holdings of funds, one fund under China Merchants Fund holds Hanyu Pharmaceutical as a significant investment. The fund, China Merchants Stable Growth Mixed A (010503), reduced its holdings by 500 shares in the second quarter, maintaining a total of 500 shares, which represents 0.02% of the fund's net value, ranking it as the ninth largest holding [2] - The China Merchants Stable Growth Mixed A fund was established on February 5, 2021, with a latest scale of 23.4958 million CNY. Year-to-date returns are 1.7%, ranking 7700 out of 8226 in its category, while the one-year return is 2.11%, ranking 7599 out of 8099. Since inception, the fund has achieved a return of 0.77% [2] - The fund manager, Chen Jiarong, has a tenure of 16 years and 313 days, with total assets under management of 51.3802 million CNY. The best return during his tenure is 45.74%, while the worst return is -4.97% [2]

Group 1 - The core point of the news is that Hanyu Pharmaceutical experienced a decline of 5.02% in its stock price, reaching 21.96 CNY per share, with a trading volume of 459 million CNY and a turnover rate of 2.78%, resulting in a total market capitalization of 19.396 billion CNY [1] - Hanyu Pharmaceutical, established on April 2, 2003, and listed on April 7, 2011, is located in the Guanlan High-tech Park, Longhua District, Shenzhen, Guangdong Province. The company primarily engages in chemical pharmaceuticals and medical devices, with 100% of its revenue derived from the pharmaceutical manufacturing sector [1] Group 2 - From the perspective of major fund holdings, one fund under China Merchants Fund has a significant position in Hanyu Pharmaceutical. The fund, named China Merchants Stable Growth Mixed A (010503), reduced its holdings by 500 shares in the second quarter, maintaining a total of 500 shares, which accounts for 0.02% of the fund's net value, ranking as the ninth largest holding [2] - The China Merchants Stable Growth Mixed A fund was established on February 5, 2021, with a latest scale of 23.4958 million CNY. Year-to-date, it has achieved a return of 1.46%, ranking 7623 out of 8171 in its category, while its one-year return is 3.14%, ranking 7659 out of 8004 [2] - The fund manager, Chen Jiarong, has a tenure of 16 years and 282 days, with the total asset scale of the fund currently at 50.5506 million CNY. During his tenure, the best fund return was 45.74%, while the worst was -4.97% [2]

Group 1 - Han Yu Pharmaceutical (300199.SZ) released its semi-annual report for 2025 on August 22, 2025 [1] - As of August 21, 2025, seven institutional investors disclosed holdings in Han Yu Pharmaceutical A-shares, totaling 44.3541 million shares, which accounts for 5.02% of the company's total share capital [1] - The institutional investors include Shenzhen High-tech Investment Group Co., Ltd., Hong Kong Central Clearing Limited, and others, with a total institutional holding ratio decreasing by 1.61 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, two public funds reduced their holdings compared to the previous quarter, including Bosera CSI Taogold Big Data 100 A and China Merchants Stable Growth Mixed A, with a slight decrease in holding ratio [1] - One insurance fund increased its holdings, specifically Fude Property Insurance Co., Ltd. - proprietary funds, with an increase of 0.1% [1] - Foreign investment sentiment showed a decrease in holdings from one foreign fund, Hong Kong Central Clearing Limited, with a slight decline in holding ratio compared to the previous quarter [1]